LEADER 04011nam  2201021z- 450 
001 9910557749803321
005 20240318195924.0
035   $a(CKB)5400000000045844
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68279
035   $a(EXLCZ)995400000000045844
100   $a20202105d2021      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAsthma$eCurrent Perspectives on Phenotypes, Endotypes, and Treatable Traits
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021
215   $a1 electronic resource (280 p.)
311   $a3-03943-859-X 
311   $a3-03943-860-3 
330   $aAsthma is a common complex and heterogeneous respiratory disease with an increasing prevalence in developed countries. Asthma is a disease consisting of different phenotypes that are driven by different mechanistic pathways (endotypes). The recognition of these phenotypes and endotypes is central to asthma management entailing prognostic and therapeutic implications. It is acknowledged that despite optimal treatment, many patients are poorly controlled, highlighting the need for phenotype-guided treatments. In this context, the emergence of novel therapies (monoclonal antibody therapy, bronchial thermoplasty) is paving the way for personalized asthma therapy. A better understanding of disease pathogenesis may enable the identification of biomarkers, mediators, novel therapeutic targets, and treatable traits. Further molecular phenotyping or endotyping of asthma will be necessary to tailor new therapeutic strategies. The present Special Issue on Asthma aims to provide the current knowledge on phenotypes and endotypes in appreciating and managing the heterogeneous condition that is asthma.
517   $aAsthma
606   $aMedicine$2bicssc
610   $aasthma
610   $alactic acidosis
610   $ahyperchloremic acidosis
610   $ahypocapnia
610   $ahypercapnia
610   $awheezing
610   $abronchial biopsies
610   $asymptom persistence
610   $aclinical remission
610   $aeosinophil
610   $aadhesion
610   $aviability
610   $aproliferation
610   $aairway smooth muscle cell
610   $apulmonary fibroblast
610   $aphenotype
610   $aacute severe asthma exacerbation
610   $anear fatal asthma
610   $asevere asthma
610   $ainflammation
610   $ainterleukin-5 (IL-5)
610   $aanti-IL-5
610   $ainterleukin-4
610   $aairway remodeling
610   $amatrix metalloproteinases-9
610   $atissue inhibitor of metalloproteinase-1
610   $aalveolar macrophages
610   $alung function
610   $abronchodilation
610   $aresistance
610   $aobstruction
610   $areproducible
610   $aspirometry
610   $aobstructive sleep apnea
610   $abronchial asthma
610   $aalternative overlap syndrome
610   $aexacerbation
610   $areactive oxygen species
610   $aPBMC
610   $amitochondrial function
610   $ainnate immunity
610   $aimmune regulation
610   $aNLRP3
610   $aIL-1?
610   $aallergic airway inflammation
610   $amicrobiome
610   $apathogenesis
610   $aimmune responses
610   $aPreDicta
610   $apreschool
610   $aFeNO
610   $aasthma-specific quality of life
610   $achronic rhinitis
610   $adisease-specific quality of life
610   $ahealth-related quality of Life (HRQLQ)
610   $achildren
610   $alongitudinal study
615  7$aMedicine
700   $aRovina$b Nikoletta$4edt$01280957
702   $aRovina$b Nikoletta$4oth
906   $aBOOK
912   $a9910557749803321
996   $aAsthma$93017748
997   $aUNINA